====== SLAMF7 ======

SLAM family member 7 is a [[protein]] that in humans is encoded by the SLAMF7 [[gene]].

The surface antigen [[CD319]] (SLAMF7) is a robust marker of normal plasma cells and malignant plasma cells in multiple [[myeloma]]. In contrast to [[CD138]] (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from delayed or even cryopreserved samples.

[[Elotuzumab]] is an antibody that targets this protein.
----
Lu et al. showed that a bispecific nano[[bioconjugate]] that enables the decoration of SLAMF7 on the surface of [[solid tumor]]s induces robust [[phagocytosis]] and activates the phagocyte [[cyclic guanosine monophosphate-adenosine monophosphate]] synthase-stimulator of [[interferon gene]]s [[cGAS-STING pathway]], sensitizing the tumors to [[immune checkpoint blockade]]. The findings support an immunological conversion strategy that uses [[nano adjuvant]]s to improve the effectiveness of [[immunotherapy]] for solid tumors
((Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer [[immunotherapy]]. Nat Nanotechnol. 2022 Nov 10. doi: 10.1038/s41565-022-01245-7. Epub ahead of print. PMID: 36357792.))